The companies said the drug showed Elquis significantly reduced the risk of stroke or systemic embolism by 21%, major bleeding by 31%, and mortality by 11%.

FORBES: Bristol-Myers, Pfizer Announce Positive Results; An FDA Approval for Pfizer

Bristol-Myers Squibb ( BMY) and Pfizer ( PFE) announced over the weekend positive results in a Phase 3 trial that compared Elquis to warfarin for the prevention of stroke or systemic embolism in patients with atrial fibrillation and at least one risk factor for stroke.

FORBES: Bristol-Myers, Pfizer Announce Positive Results; An FDA Approval for Pfizer